The structural puzzle of how serpin serine proteinase inhibitors work

BioEssays

Volumn 18, Issue 6, 1996, Pages 453-464

  Wright, H Tonie ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERINE PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; SERPINS;

EID: 0030159797     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.950180607     Document Type: Article

References (74)

1. Bode, W. and Huber, W. (1991). Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204, 433-451.
2. Travis, J. and Salvesen, G. (1983). Human plasma proteinase inhibitors. Ann. Rev. Biochem. 52, 655-709.
3. Huber, R. and Carrell, R.W. (1989). Implications of the three-dimensional structure and function of serpins. Biochemistry 28, 8951-8966.
4. Potempa, J., Korzus, E. and Travis, J. (1994). The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269, 15957-15960.
5. Stein, P.E. and Carrell, R.W. (1995). What do dysfunctional serpins tell us about molecular mobility and disease? Nature Structural Biology 2, 95-113.
6. Engh, R.A., Schulze, A.J., Huber, R. and Bode, W. (1993). Serpin structures. Behring Inst. Mitt. No. 93, 41-62.
7. Schulze, A.J., Huber, R., Bode, W. and Engh, R.A. (1994). Structural aspects of serpin inhibition. FEBS Lett. 344, 117-124.
8. Loebermann, H., Tokuoka, R., Deisenhofer, J. and Huber, R. (1994). Human α1-proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177, 531-556.
9. Baumann, U., Huber, R., Bode, W., Grosse, D., Lesjak, M. and Laurell, C.B. (1991). Crystal structure of cleaved human α1-antichymotrypsin at 2.7Å resolution and its comparison with other serpins. J. Mol. Biol. 218, 595-606.
10. Baumann, U., Bode, W., Huber, R., Travis, J. and Potempa, J. (1992). Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95Å resolution. J. Mol. Biol. 226, 1207-1218.
11. Mourey, L., Samama, J.-P., Delarue, M., Petitou, M., Choay, J. and Moras, D. (1993). Crystal structure of cleaved bovine antithrombin III at 3.2Å resolution. J. Mol. Biol. 232, 223-241.
12. Wright, H.T., Qian, H.Z. and Huber, R. (1990). Crystal structure of plakalbumin, a protelytically nicked form of ovalbumin. J. Mol. Biol. 213, 513-528.
13. Engh, R.A., Wright, H.T. and Huber, R. (1990). Modelling the intact form of the alpha-1-proteinase inhibitor. Prot. Engin. 3, 469-477.
14. Stein, P., Leslie, A.G.W., Finch, J.T., Turnell, W.G., McLaughlin, P.J. and Carrell, R.W. (1991). Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 347, 99-102.
15. Wei, A., Rubin, H., Cooperman, B.S. and Christianson, D.W. (1994). Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Structural Biology 1, 251-257.
16. Hekman, C.M. and Loskutoff, D.J. (1985). Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260, 11581-11587.
17. Carrell, R.W., Stein, P.E., Fermi, G. and Wardell, M.R. (1994). Biological implications of a 3Å structure of dimeric antithrombin. Structure 2, 257-270.
18. Lomas, D.A., Elliott, P.R., Chang, W.-S.W., Wardell, M.R. and Carrell, R.W. (1995). Preparation and characterization of latent α1-antitrypsin. J. Biol. Chem. 270, 5282-5288.
19. Mottonen, J. et al. (1992). Structural basis of latency in plasminogen activator Inhibitor-1. Nature 355, 270-273.
20. Schreuder, H.A. et al. (1994). The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Structural Biology 1, 48-54.
21. Stein, P. and Chothia, C. (1991). Serpin tertiary structure transformation. J. Mol. Biol. 221, 615-621.
22. Tucker, H.M., Mottonen, J., Goldsmith, E.J. and Gerard, R.D. (1995). Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nature Structural Biology 2, 442-445.
23. Wright, H.T. and Scandale, J.N. (1995). Structural basis for serpin inhibitor activity. Prot. Struct. Funct. Genet. 22, 210-225.
24. Berkenpas, M.B., Lawrence, D.A. and Ginsburg, D. (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977.
25. Novotny, J. and Bruccoleri, R.E. (1986). Correlation among sites of limited proteolysis, enzyme accessibility and segmental mobility. FEBS Lett. 211, 185-189.
26. Fontana, A. (1989). Limited proteolysis of globular proteins occurs at exposed and flexible loops. In Highlights of Modem Biochemistry (ed. A. Kotyk, J. Skoda, B. Paces and V. Kostka), pp. 1711-1726. VSP International Science Publishers: Zeist, the Netherlands.
27. Hubbard, S.J., Campbell, S.F. and Thornton, J.M. (1991). Molecular recognition: Conformational analysis of limited proteolytic sites and serine proteinase inhibitors. J. Mol. Biol. 220, 507-530.
28. 1H NMR probe for the mobility in the reactive center loops of serpins: Spin-echo studies of native and modified forms of ovalbumin and α1-proteinase inhibitor. Biochemistry 30, 9054-9060.
29. Mast, A.E., Enghild, J.J. and Salvesen, G. (1992). Conformation of the reactive site loop of α1-proteinase inhibitor probed by limited proteolysis. Biochemistry 31, 2720-2728.
30. Bode, W. and Huber, R. (1992). Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204, 433-451.
31. Soman, K., Yang, A.S., Honig, B. and Fletterick, R. (1989). Electrical potentials in trypsin isozymes. Biochemistry 26, 9918-9926.
32. Skriver, K. et al. (1991). Substrate properties of C1 inhibitor Ma (alanine 434 → glutamic acid). Genetic and structural evidence suggesting that the P12 region contains critical determinants of serine protease inhibitor/substrate status. J. Biol. Chem. 266, 9216-9221.
33. Shieh, B.H., Potempa, J. and Travis, J. (1989). The use of α2-antiplasmin as a model for the demonstration of complex reversibility in serpins. J. Biol. Chem. 264, 13420-13423.
34. Matheson, N. R., van Halbeek, H. and Travis, J. (1991). Evidence of a tetrahedral intermediate complex during serpin-proteinase interactions. J. Biol. Chem. 266, 13489-13491.
35. Owen, W.G., Penick, G.D., Yoder, E. and Poole, B.L. (1976). Evidence for an ester bond between thrombin and heparin cofactor. Thromb. Haemostas. 35, 87-95.
36. Cohen, A.B., Geczy, D. and James, H.L. (1978). Interaction of human α-1-antitrypsin with porcine trypsin. Biochemistry 17, 392-400.
37. Lawrence, D.A. et al. (1995). Serpin-protease complexes are trapped as stable acyl intermediates. J. Biol. Chem. 270, 25309-25312.
38. Rubin, H. et al. (1990). Cloning, expression, purification, and biological activity of recombinant native and variant human α1-antichymotrypsins. J. Biol. Chem. 265, 1199-1207.
39. Patston, P.A., Gettins, P., Beechem, J. and Schapira, M. (1991). Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30, 8876-8882.
40. Cooperman, B.S., Stavridi, E., Nickbarg, E., Rescoria, E., Schlechter, N.M. and Rubin, H. (1993). Antichymotrypsin interaction with chymotrypsin. J. Biol. Chem. 268, 23616-23625.
41. Longstaff, C. and Gaffney, P.J. (1991). Serpin-serine protease binding kinetics: α2-antiplasmin as a model inhibitor. Biochemistry 30, 979-986.
42. Christensen, S., Sottrup-Jensen, L. and Christensen, U. (1995). Stopped-flow fluorescence kinetics of bovine α2-antiplasmin inhibition of bovine midplasmin. Biochem. J. 305, 97-102.
43. Rubin, H. et al. (1994). Conversion of α1-antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities. Biochemistry 33, 7627-7633.
44. Carrell, R.W. and Owen, M.C. (1985). Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 322, 730-732.
45. Gettins, P. and Harten, B. (1988). Properties of thrombin- and elastase-modified human antithrombin III. Biochemistry 27, 3634-3639.
46. Bruch, M., Weiss, V. and Engel, J. (1988). Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263, 16626-16630.
47. Gettins, P. (1989). Absence of large-scale conformational change upon limited proteolysis of ovalbumin, the prototypic serpin. J. Biol. Chem. 265, 3781-3785.
48. Stein, P.E., Tewkesbury, D.A. and Carrell, R.W. (1989). Ovalbumin and angiotensinogen lack serpin S-R conformational change. Biochem. J. 262, 103-107.
49. Pemberton, P.A., Stein, P.E., Pepys, M.B., Potter, J.M. and Carrell, R.W. (1988). Hormone binding globulins undergo serpin conformational change in inflammation. Nature 336, 257-258.
50. Munch, M., Heegaard, C., Jensen, P.H. and Andreasen, P.A. (1991). Type-1 inhibitor of plasminogen activators. FEBS Lett. 295, 102-106.
51. Sancho, E., Declerck, P.J., Price, N.C., Kelly, S.M. and Booth, N.A. (1995). Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved form. Biochemistry 34, 1064-1069.
52. Schulze, A.J., Huber, R., Degryse, E., Speck, D. and Bischoff, R. (1991). Inhibitory activity and conformation transition of α1-proteinase inhibitor variants. Eur. J. Biochem. 202, 1147-1155.
53. Hood, D.B., Huntlngton, J.A. and Gettins, P.G.W. (1994). α1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 33, 8538-8547.
54. Lawrence, D.A., Olson, S.T., Palaniappan, S. and Ginsburg, D. (1994). Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J. Biol. Chem. 269, 27657-27662.
55. Wright, H.T. and Blajchman, M.A. (1994). Proteolytically cleaved mutant antithrombin-Hamilton has high stability to denaturation characteristic of wild type inhibitor serpins. FEBS Lett. 348, 14-16.
56. Carrell, R.W., Evans, D.L. and Stein, P. (1991). Mobile reactive centre of serpins and the control of thrombosis. Nature 353, 576-578.
57. Schulze, A.J., Baumann, U., Knot, S., Jäger, E., Huber, R. and Laurell, C.-B. (1990). Structural transition of α1-antrtrypsin by a peptide sequentially similar to beta-strand s4A. Eur. J. Biochem. 194, 51-56.
58. Schulze, A.J., Frohnert P.W., Engh, R.A. and Huber, R. (1992). Evidence for the extent of insertion of the active site loop of intact α1-proteinase inhibitor in β-sheet A. Biochemistry 31, 7560-7565.
59. White, D., Abraham, G., Carter, C., Kakkas, V.V. and Cooper, D.N. (1992). A novel missense mutation in the antithrombin III gene (Ser349 to Pro) causing recurrent venous thrombosis. Hum. Genet. 90, 472-473.
60. Holmes, W.E. et al. (1987). α2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science 238, 209-211.
61. Mast, A.E., Enghild, J.J., Pizzo, S.V. and Salvesen, G. (1991). Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: Comparison of α1-proteinase inhibitor, α1-antichymotrypsin, antithrombin III, α2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 30, 1723-1730.
62. Pizzo, S.V. (1989). Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am. J. Medicine 87, suppl. 3B, 10S-14S.
63. Joslin, G., Wittwer, A., Adams, S., Tollefsen, D.M., August, A. and Perlmutter, D.H. (1993). Cross-competition for binding of α1-antitrypsin (α1 AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified α1 AT*. J. Biol. Chem. 268, 1886-1893.
64. Zagorski, M.G. and Barrow, C.J. (1992). NMR studies of amyloid β-peptides: proton assignments, secondary structure, and mechanism of an α-helix → β-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry 31, 5621-5631.
65. Soto, C., Brañes, M.C., Alvarez, J. and Inestrosa, N.C. (1994). Structural determinants of the Alzheimer's amyloid β-peptide. J. Neurochem. 63, 1191-1198.
66. Safar, J., Roller, P.R., Gajdusek, D.C. and Gibbs, C.J.Jr. (1993). Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268, 20276-20284.
67. Pan, K.-M. et al. (1993). Conversion of a-helices into β-sheet features in the formation of scrapie prion proteins. Proc. Natl Acad. Sci. USA 90, 10962-10966.
68. Jeppsson, J.-O. (1976). Amino-acid substitution Glu → Lys in α1-proteinase inhibitor Piz. FEBS Lett. 65, 195-197.
69. 39 → Cys). Human Genetics 84, 55-58.
70. Matsunaga, E., Shiokawa, S., Nakamura, H., Maruyama, T., Tsuda, K. and Fukumaki, Y. (1990). Molecular analysis of the gene of the α1-antitrypsin deficiency variant, M Nichinan. Am. J. Hum. Genet. 84, 55-58.
71. iiyama (Ser 53 (TCC) to phenylalanine 53 (TTC)). J. Biol. Chem. 266, 12627-12632.
72. 53 → Phe). Further evidence for intracellular loop-sheet polymerisation. J. Biol. Chem. 268, 15333-15335.
73. Lomas, D.A., Evans, D.LI., Finch, J.T. and Carrell, R.W. (1992). The mechanism of Z α1-proteinase inhibitor accumulation in the liver. Nature 357, 605-607.
74. Kraulis, P. (1991). MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Applied Cryst. 24, 946-950.